A Phase I Study of AG-636 for Patients with Advanced Lymphoma

Share
Print

Full Title

A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Purpose

The purpose of this study is to find the highest dose of the investigational drug AG-636 that can be given safely in patients with advanced lymphoma that cannot be cured with standard therapies. AG-636 blocks a protein called DHODH that is involved in making some of the building blocks needed to produce DNA and RNA, the genetic “instruction books” for cells. Blocking DHODH and reducing cancer cells’ ability to produce these necessary genetic instructions may slow or stop the growth of cancer.

AG-636 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have advanced Hodgkin or non-Hodgkin lymphoma that has continued to grow despite treatment and cannot be cured with standard therapies.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Gottfried von Keudell at 212-639-3748.

Protocol

19-183

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators